Mer­ck suf­fers rare Keytru­da set­back as the block­buster fails a PhI­II prostate can­cer test with Lyn­parza

Mer­ck’s can­cer drug Keytru­da has be­come one of the best-sell­ing med­i­cines on the plan­et thanks to a rig­or­ous clin­i­cal de­vel­op­ment pro­gram that’s racked up win …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER